EPAS1 and cancer: In addition, 61% (n = 22/36) of non-metastasizing tumours had high EPAS1 mRNA overexpression, whereas 78% (n = 7/9) of metastasizing malignant tumours had low EPAS1 mRNA expression (Table 4; p = 0.057).